Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA03 - Biomarkers for Immunotherapy: Are All Relevant?
- 10:45 - 11:45
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
MA03.02 - TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
10:50 - 10:55 | Presenter: Edward B Garon
- Abstract
Loading...
-
+
P14 - Immunotherapy (Phase II/III Trials) - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P14.07 - PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Alexander Spira
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.05 - A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)
00:00 - 00:00 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
P53 - Novel Therapeutics and Targeted Therapies - Others
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P53.06 - A Multi-Phase Quality Initiative to Improve Processes of Care for Non-small Cell Lung Cancer (NSCLC) in US Community Cancer Centers
00:00 - 00:00 | Presenter: Matthew Smeltzer
- Abstract
Loading...
-
+
P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
P60.11 - Trends in Molecular Testing for Metastatic Non-Small Cell Lung Cancer in The US Oncology Network Community Practices
00:00 - 00:00 | Presenter: Nicholas J Robert
- Abstract
Loading... -
+
P60.13 - MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study
00:00 - 00:00 | Presenter: Makenzi Colleen Evangelist
- Abstract
Loading...
-
+
IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape with Novel Strategies
- 13:15 - 14:15
- 9/09/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
- Moderators:David R. Gandara, Alexander Spira, Afshin Dowlati
-
+
IS05.01 - Welcome and Introductions
13:15 - 13:20 | Presenter: David R. Gandara
- Abstract
No abstract available for this presentation
-
+
IS05.02 - The Evolving Biomarker Landscape in Advanced NSCLC
13:20 - 13:35 | Presenter: David R. Gandara
- Abstract
No abstract available for this presentation
-
+
IS05.03 - KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC
13:35 - 13:50 | Presenter: Alexander Spira
- Abstract
No abstract available for this presentation
-
+
IS05.04 - Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC
13:50 - 14:05 | Presenter: Afshin Dowlati
- Abstract
No abstract available for this presentation
-
+
IS05.05 - Discussion
14:05 - 14:15
- Abstract
No abstract available for this presentation
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.01 - Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
18:45 - 18:55 | Presenter: Alexander Spira
- Abstract
Loading... -
+
OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
19:05 - 19:15 | Presenter: Alexander Spira
- Abstract
Loading...
-
+
MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC
- 18:45 - 19:45
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
MA14.03 - Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib
18:55 - 19:00 | Presenter: Ferdinandos Skoulidis
- Abstract
Loading...